Brokerages Set Vascular Biogenics Ltd (VBLT) PT at $3.33

Vascular Biogenics Ltd (NASDAQ:VBLT) has earned an average rating of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $3.33.

Several research analysts have commented on VBLT shares. Zacks Investment Research lowered Vascular Biogenics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 9th. ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.

A hedge fund recently raised its stake in Vascular Biogenics stock. Raymond James & Associates raised its stake in Vascular Biogenics Ltd (NASDAQ:VBLT) by 71.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,466 shares of the biopharmaceutical company’s stock after purchasing an additional 23,124 shares during the quarter. Raymond James & Associates owned about 0.19% of Vascular Biogenics worth $394,000 at the end of the most recent quarter. 7.00% of the stock is owned by institutional investors and hedge funds.

Vascular Biogenics traded up $0.07, hitting $1.78, during mid-day trading on Friday, Marketbeat.com reports. The company had a trading volume of 161,283 shares, compared to its average volume of 115,964. Vascular Biogenics has a 1 year low of $1.60 and a 1 year high of $9.05. The firm has a market capitalization of $50.92 million, a PE ratio of -4.80 and a beta of -1.79.

Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings data on Thursday, May 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The business had revenue of $0.16 million during the quarter. research analysts predict that Vascular Biogenics will post -0.77 EPS for the current fiscal year.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Further Reading: How to Track your Portfolio in Google Finance

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply